We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

By LabMedica International staff writers
Posted on 27 Jan 2015
A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process can be blocked by the immune factor interferon lambda (INFlambda).

Norovirus causes more than 90% of global epidemic nonbacterial gastroenteritis, and it is thought to be spread by a subset of people who maintain a low-level persistent infection. More...
How the enteric virus establishes such persistent infections is not well understood.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) have turned up some interesting new insights regarding how norovirus infection becomes established and is maintained. They reported in the November 27, 2014, online edition of the journal Science that establishment of the viral infection in a mouse model depended on interaction with certain gut bacteria and that the infection could be prevented by treatment with antibiotics. Viral infection could be established following replenishment of the bacterial microbiota. Antibiotics did not prevent tissue infection or affect systemic viral replication, but acted specifically in the intestine.

In a second paper in the same issue of the journal Science, the investigators reported that while the cytokines interferon alpha (IFNalpha) and interferon beta (IFNbeta) prevented the systemic spread of norovirus in the mouse model, only IFNlambda controlled persistent enteric infection. Infection-dependent induction of IFNlambda was governed by the viral capsid protein and correlated with diminished enteric persistence. Treatment of established infection with IFNlambda cured mice in a manner that required non-hematopoietic cell expression of the IFNlambda receptor, Ifnlr1, and was independent of adaptive immunity.

“I believe that is a new concept in immunology,” said senior author Dr. Herbert W. Virgin, professor of pathology and immunology at Washington University School of Medicine. “We thought that interferon lambda and other related molecules in the immune system could only contain viral infections until other parts of the immune system, including antibodies and T-cells, finished the job.”

“The virus actually requires the bacteria to create a persistent infection,” said Dr. Virgin. “The virus appears to have a symbiotic relationship with the bacteria — they share the job of establishing persistence. We need a much more detailed understanding of how antibiotic treatment affects the links among host, bacteria, and virus.”

Related Links:

Washington University School of Medicine



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.